Teva Pharmaceutical Industries (TEVA)
Teva Pharmaceutical Industries Market Cap: 36.23B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
TEVA Market Cap Rankings
| Overall | 97th percentile | 126 of 4665 |
| Sector | 96th percentile | 16 of 527 in Healthcare |
| Industry | 95th percentile | 2 of 42 in Drug Manufacturers - Other |
TEVA Market Cap Range, Past 5 Years
| Minimum | 32.94B | Sep 2011 |
| Maximum | 58.73B | Mar 2010 |
| Average | 41.83B |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these TEVA related companies
TEVA News
$TARO super-cheap at $37 $TEVA $AMRN $PFE $PRGO $MYL $PFE http://stks.co/43a0
about 19 hours ago by imhobutdydd
about 19 hours ago by imhobutdydd
Teva to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
May 30, 12:33PM Business Wire
May 30, 12:33PM Business Wire
@mydanilo It had nothing to do with those news. That was already priced in. Seems like Patent news regarding $TEVA and $GSK was the trigger.
about 3 days ago by mitrado
about 3 days ago by mitrado
Teva Pharmaceutical Inds, VeriFone Systems Among Stocks Down on Above-average Volume Tuesday
May 29, 4:34PM Fox Business
May 29, 4:34PM Fox Business
$AMRN up following news that $Teva and $PRX lost a bid to sell the generic form of $GSK Lovaza. http://stks.co/41F0
about 3 days ago by abubnic
about 3 days ago by abubnic
Teva (TEVA), Par Pharma (NPRX) said to lose bid to sell the generic form of Glaxo's (GSK) Lovaza
May 29, 3:20PM Street Insider
May 29, 3:20PM Street Insider
Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Copaxone Preview
May 29, 8:24AM Street Insider
May 29, 8:24AM Street Insider
Barclays Maintains an 'Equalweight' on Teva Pharma (TEVA); Adjusting Estimates After Business Update
May 25, 1:21PM Street Insider
May 25, 1:21PM Street Insider
Jeremy Levin is checking all the right boxes at $TEVA. Set realistic expectations, cut the fat/fix what you have, then look for new growth.
about 7 days ago by bradloncar
about 7 days ago by bradloncar
UBS Maintains a 'Buy' on Teva Pharma (TEVA); CEO Highlights From Conference Call
May 25, 10:52AM Street Insider
May 25, 10:52AM Street Insider
$TEVA keeps going up on bad news. WTF!? Can anyone explain this insanity?
about 7 days ago by mitrado
about 7 days ago by mitrado
Canaccord Genuity Maintains a 'Buy' on Teva Pharma (TEVA); Adjusting Estimates; Copaxone Still In Focus
May 25, 9:39AM Street Insider
May 25, 9:39AM Street Insider
UPDATE: Citigroup Reduces PT to $49 on Teva Pharmaceuticals on Lower Estimates
May 25, 8:07AM Benzinga
May 25, 8:07AM Benzinga
Needham & Company Maintains a 'Hold' on Teva Pharma (TEVA); Adjusting Estimates
May 25, 7:55AM Street Insider
May 25, 7:55AM Street Insider
wow $TEVA getting murdered. Puts I alerted this morning at .39 are now at .68.+74% ...but I already alerted to sell at .52 *sighs*
about 8 days ago by OptionRunners
about 8 days ago by OptionRunners
$TEVA 37.5x June puts, just alerted to sell at .52 from my alert this morning at .39. Quick +33.3% gain.
about 8 days ago by OptionRunners
about 8 days ago by OptionRunners
Nice drop on $TEVA from the highs! Lowered 2012 guidance. Alerted the 37.5x June puts this morning at .39. Now at .50 +28.2%
about 8 days ago by OptionRunners
about 8 days ago by OptionRunners
Blueberries, Gold Bond, Ovaltine and Obesity: The Makings for a Very Good Story
May 23, 5:03PM Benzinga
May 23, 5:03PM Benzinga
Bob McDonald’s Quandary: Save the World or Maintain P&G’s Dividend, Yielding 3.5% http://stks.co/3xc5 $PG $K $DMND $TEVA
about 9 days ago by ycharts
about 9 days ago by ycharts
@bradloncar Thanks. I guess I just have a suspicious mind. This is the same guy that sits on $TEVA board,right ?? newly elected 3 yrs.
about 10 days ago by stockhound
about 10 days ago by stockhound
W his left-over pocket change, Dr. Frost also invests in $PBTH. Made his fortune w investments in $TEVA. $OPK http://stks.co/3w1h
about 10 days ago by abubnic
about 10 days ago by abubnic
$SBUX $PCLN $TEVA $CSCO $QQQ
15 Most Oversold Nasdaq 100 Stocks
http://stks.co/3vBl
about 11 days ago by TomAspray
about 11 days ago by TomAspray
Canaccord Genuity on Pharmaceuticals: Generic Valuation at Historical Trough Level Ahead of Meetings
May 21, 10:05AM Street Insider
May 21, 10:05AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| TEVA | 38.47 | -0.72 | -1.84% | 36.91B |
| TEU | 7.85 | -0.08 | -1.01% | |
| TESS | 18.21 | -0.95 | -4.96% | 149.06M |
| TER | 13.67 | -0.78 | -5.40% | 2.694B |
| TEO | 11.96 | -0.15 | -1.24% | 2.384B |
| Y | 326.19 | -2.81 | -0.85% | 2.813B |
| XXIA | 10.28 | -0.30 | -2.84% | 748.32M |
| XWES | 3.40 | -0.11 | -3.13% | 40.36M |
| XUE | 3.46 | -0.13 | -3.62% | 248.32M |
| XTXI | 13.32 | -0.19 | -1.41% | 640.24M |
